$CARM
Carisma Therapeutics Inc

2014 Q3 Form 10-Q Financial Statement

#000119312514308418 Filed on August 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $539.0K $761.0K $202.0K
YoY Change -13.34% 276.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.270M $2.050M $880.0K
YoY Change 187.34% 132.95%
% of Gross Profit
Research & Development $8.872M $6.754M $2.704M
YoY Change 162.8% 149.78%
% of Gross Profit
Depreciation & Amortization $100.0K $110.0K $110.0K
YoY Change -9.09% 0.0% -50.0%
% of Gross Profit
Operating Expenses $11.14M $8.806M $3.585M
YoY Change 167.68% 145.63%
Operating Profit -$10.60M -$8.045M -$3.383M
YoY Change 199.49% 137.81%
Interest Expense -$74.00K -$79.00K -$137.0K
YoY Change -74.39% -42.34%
% of Operating Profit
Other Income/Expense, Net -$72.00K -$76.00K -$251.0K
YoY Change -73.63% -69.72%
Pretax Income -$10.67M -$8.120M -$3.630M
YoY Change 180.05% 123.69%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.67M -$8.121M -$3.634M
YoY Change 179.94% 123.47%
Net Earnings / Revenue -1980.33% -1067.15% -1799.01%
Basic Earnings Per Share
Diluted Earnings Per Share -$662.7K -$505.6K -$2.213M
COMMON SHARES
Basic Shares Outstanding 16.27M shares 16.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.90M $45.00M $7.100M
YoY Change 820.51% 533.8%
Cash & Equivalents $35.94M $45.03M $7.078M
Short-Term Investments
Other Short-Term Assets $300.0K $1.000M $600.0K
YoY Change 50.0% 66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $36.29M $46.03M $7.700M
YoY Change 764.07% 497.83%
LONG-TERM ASSETS
Property, Plant & Equipment $585.0K $682.0K $1.000M
YoY Change -35.0% -31.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.00K $15.00K $0.00
YoY Change
Total Long-Term Assets $690.0K $791.0K $1.000M
YoY Change -23.33% -20.9%
TOTAL ASSETS
Total Short-Term Assets $36.29M $46.03M $7.700M
Total Long-Term Assets $690.0K $791.0K $1.000M
Total Assets $36.98M $46.82M $8.700M
YoY Change 625.12% 438.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.588M $2.602M $700.0K
YoY Change 269.71% 271.71%
Accrued Expenses $1.656M $1.140M $300.0K
YoY Change 452.0% 280.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $3.200M
YoY Change -100.0% -100.0%
Long-Term Debt Due $1.600M $1.600M $1.300M
YoY Change -5.88% 23.08%
Total Short-Term Liabilities $6.507M $6.027M $6.700M
YoY Change -8.35% -10.04%
LONG-TERM LIABILITIES
Long-Term Debt $1.600M $2.100M $3.700M
YoY Change -51.52% -43.24%
Other Long-Term Liabilities $100.0K $100.0K $1.000M
YoY Change -87.5% -90.0%
Total Long-Term Liabilities $1.700M $2.200M $4.700M
YoY Change -58.54% -53.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.507M $6.027M $6.700M
Total Long-Term Liabilities $1.700M $2.200M $4.700M
Total Liabilities $8.200M $8.200M $11.40M
YoY Change -26.79% -28.07%
SHAREHOLDERS EQUITY
Retained Earnings -$83.61M -$72.94M
YoY Change
Common Stock $16.00K $16.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.78M $38.62M -$2.700M
YoY Change
Total Liabilities & Shareholders Equity $36.98M $46.82M $8.700M
YoY Change 625.12% 438.21%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$10.67M -$8.121M -$3.634M
YoY Change 179.94% 123.47%
Depreciation, Depletion And Amortization $100.0K $110.0K $110.0K
YoY Change -9.09% 0.0% -50.0%
Cash From Operating Activities -$8.690M -$8.450M -$1.840M
YoY Change 173.27% 359.24% -81.4%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$80.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$80.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -390.0K -410.0K 3.470M
YoY Change 3800.0% -111.82% -86.16%
NET CHANGE
Cash From Operating Activities -8.690M -8.450M -1.840M
Cash From Investing Activities -10.00K -80.00K 0.000
Cash From Financing Activities -390.0K -410.0K 3.470M
Net Change In Cash -9.090M -8.940M 1.630M
YoY Change 184.95% -648.47% -89.25%
FREE CASH FLOW
Cash From Operating Activities -$8.690M -$8.450M -$1.840M
Capital Expenditures -$10.00K -$80.00K $0.00
Free Cash Flow -$8.680M -$8.370M -$1.840M
YoY Change 172.96% 354.89% -81.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16272723 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7078000
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16092545 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
470531 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16092545 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.86
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1490979 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.35
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1126768 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.20
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1140000
CY2014Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111544000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2602000
CY2014Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1642000
CY2014Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
157000
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6027000
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
478000
CY2014Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
38623000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72937000
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
643000
CY2014Q2 us-gaap Construction Payable Current
ConstructionPayableCurrent
404000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
16000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46824000
CY2014Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
2055000
CY2014Q2 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
7000
CY2014Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
112000
CY2014Q2 us-gaap Interest Payable Current
InterestPayableCurrent
100000
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Assets Current
AssetsCurrent
46033000
CY2014Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2014Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
45031000
CY2014Q2 us-gaap Assets
Assets
46824000
CY2014Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
45031000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45031000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1002000
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4100000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
682000
CY2014Q2 ebio Estimated Milestone Payment To Be Received
EstimatedMilestonePaymentToBeReceived
25000000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7882000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
850000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-54332000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1636137 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1636137 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.39
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1346238 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
77688009 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3260000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1746000
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1642000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
182000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5353000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
346000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
297000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57594000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1115000
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
297000
CY2013Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
62000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11237000
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2876000
CY2013Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
10000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
355000
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
79000
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
297000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
297000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
8030000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2354000
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
7942000
CY2013Q4 us-gaap Assets
Assets
11237000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
7942000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7942000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
88000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
759000
CY2013Q4 ebio Deferred Offering Cost
DeferredOfferingCost
180000
CY2013Q2 us-gaap Collaborative Arrangement Nature And Purpose
CollaborativeArrangementNatureAndPurpose
Under this agreement, the Company and ThromboGenics are collaborating to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease.
CY2013Q2 us-gaap Collaborative Arrangement Rights And Obligations
CollaborativeArrangementRightsAndObligations
The Company has granted ThromboGenics an exclusive, sublicensable, royalty-bearing license under the Company's rights in these patent rights and know-how, as well as under any other patent rights and know-how that the Company controls during the research term that are necessary for ThromboGenics to perform its obligations to research, develop, manufacture and commercialize collaboration products.
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1285000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7257000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.53
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8345395 shares
us-gaap Revenues
Revenues
202000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
274000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10956000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
62000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-216000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8818000
us-gaap Interest Paid
InterestPaid
120000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-328000
us-gaap Net Income Loss
NetIncomeLoss
-9146000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
114000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1820000
us-gaap Paid In Kind Interest
PaidInKindInterest
18000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6453000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3000000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1950000
us-gaap Share Based Compensation
ShareBasedCompensation
429000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
228000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-804000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-157000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-419000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7200000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1810000
us-gaap Operating Expenses
OperatingExpenses
9020000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3500000
ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
287000
dei Trading Symbol
TradingSymbol
EBIO
dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M29D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12863000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.66
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13483000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
186115 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M28D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36612 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4762 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1668157 shares
us-gaap Revenues
Revenues
1329000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
913000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15862000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
833000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-163000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15234000
us-gaap Interest Paid
InterestPaid
123000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-109000
us-gaap Net Income Loss
NetIncomeLoss
-15343000
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.44
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
132000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3990000
us-gaap Paid In Kind Interest
PaidInKindInterest
18000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
50704000
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-715000
us-gaap Share Based Compensation
ShareBasedCompensation
1137000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
209000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
37089000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-132000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
468000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1706000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
51505000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12573000
us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
519000
us-gaap Operating Expenses
OperatingExpenses
16563000
ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
56678000
ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
247000
ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0
ebio Collaborative Arrangement Date Of Agreement
CollaborativeArrangementDateOfAgreement
2013-05-28
ebio Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue
-50000
ebio Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Reclassification To Equity
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityReclassificationToEquity
247000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1322000 shares
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-114000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3383000
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-251000
CY2013Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-137000
CY2013Q2 us-gaap Revenues
Revenues
202000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4551000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-3634000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
881000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
390000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2704000
CY2013Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
917000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
3585000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16055000 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2014Q2 us-gaap Revenues
Revenues
761000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8121000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-79000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8045000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-76000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-8121000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2052000
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
501000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6754000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
8806000
CY2014Q2 ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0

Files In Submission

Name View Source Status
0001193125-14-308418-index-headers.html Edgar Link pending
0001193125-14-308418-index.html Edgar Link pending
0001193125-14-308418.txt Edgar Link pending
0001193125-14-308418-xbrl.zip Edgar Link pending
d759136d10q.htm Edgar Link pending
d759136dex311.htm Edgar Link pending
d759136dex312.htm Edgar Link pending
d759136dex321.htm Edgar Link pending
ebio-20140630.xml Edgar Link completed
ebio-20140630.xsd Edgar Link pending
ebio-20140630_cal.xml Edgar Link unprocessable
ebio-20140630_def.xml Edgar Link unprocessable
ebio-20140630_lab.xml Edgar Link unprocessable
ebio-20140630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending